Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.

Literature DB >> 25941622

The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.

Anne Kleijn¹, Jenneke Kloezeman¹, Elike Treffers-Westerlaken², Giulia Fulci³, Sieger Leenstra¹, Clemens Dirven¹, Reno Debets², Martine Lamfers¹.

Abstract

Oncolytic viruses selectively lyse tumor cells, making these agents a promising treatment modality for glioma. Accumulating data suggest that the immune system plays an important role in the anti-glioma activity of oncolytic viruses. In an immune competent glioma model, the therapeutic effect of the oncolytic adenovirus Delta24-RGD was found to depend primarily on antitumor immune responses.

Entities: Disease Species

Keywords: adenovirus; antitumor immunity; glioma; immune response; virotherapy

Year: 2014 PMID： 25941622 PMCID： PMC4292709 DOI： 10.4161/21624011.2014.955697

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

9 in total

1. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death.

Authors: Hong Jiang; Candelaria Gomez-Manzano; Hiroshi Aoki; Marta M Alonso; Seiji Kondo; Frank McCormick; Jing Xu; Yasuko Kondo; B Nebiyou Bekele; Howard Colman; Frederick F Lang; Juan Fueyo
Journal: J Natl Cancer Inst Date: 2007-09-11 Impact factor: 13.506

2. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy.

Authors: Tünde Szatmári; Katalin Lumniczky; Szilvia Désaknai; Stéphane Trajcevski; Egon J Hídvégi; Hirofumi Hamada; Géza Sáfrány
Journal: Cancer Sci Date: 2006-06 Impact factor: 6.716

Review 3. Mechanisms of immune evasion by gliomas.

Authors: Cleo E Rolle; Sadhak Sengupta; Maciej S Lesniak
Journal: Adv Exp Med Biol Date: 2012 Impact factor: 2.622

4. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.

Authors: Juan Fueyo; Ramon Alemany; Candelaria Gomez-Manzano; Gregory N Fuller; Asadullah Khan; Charles A Conrad; Ta-Jen Liu; Hong Jiang; Michael G Lemoine; Kaori Suzuki; Raymond Sawaya; David T Curiel; W K Alfred Yung; Frederick F Lang
Journal: J Natl Cancer Inst Date: 2003-05-07 Impact factor: 13.506

5. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.

Authors: Martine L M Lamfers; Sander Idema; Lisette Bosscher; Stan Heukelom; Sharif Moeniralm; Ida H van der Meulen-Muileman; Renée M Overmeer; Paul van der Valk; Victor W van Beusechem; Winald R Gerritsen; W Peter Vandertop; Clemens M F Dirven
Journal: Clin Cancer Res Date: 2007-12-15 Impact factor: 12.531

6. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.

Authors: K Ueki; Y Ono; J W Henson; J T Efird; A von Deimling; D N Louis
Journal: Cancer Res Date: 1996-01-01 Impact factor: 12.701

7. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.

Authors: Christopher A Alvarez-Breckenridge; Jianhua Yu; Richard Price; Jeffrey Wojton; Jason Pradarelli; Hsiaoyin Mao; Min Wei; Yan Wang; Shun He; Jayson Hardcastle; Soledad A Fernandez; Balveen Kaur; Sean E Lawler; Eric Vivier; Ofer Mandelboim; Alessandro Moretta; Michael A Caligiuri; E Antonio Chiocca
Journal: Nat Med Date: 2012-11-25 Impact factor: 53.440

Review 8. Oncolytic virotherapy.

Authors: Stephen J Russell; Kah-Whye Peng; John C Bell
Journal: Nat Biotechnol Date: 2012-07-10 Impact factor: 54.908

9. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

Authors: Anne Kleijn; Jenneke Kloezeman; Elike Treffers-Westerlaken; Giulia Fulci; Sieger Leenstra; Clemens Dirven; Reno Debets; Martine Lamfers
Journal: PLoS One Date: 2014-05-27 Impact factor: 3.240

9 in total

10 in total

Review 1. Trial Watch-Oncolytic viruses and cancer therapy.

Authors: Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2015-12-08 Impact factor: 8.110

2. Deficiency of the IRE1α-Autophagy Axis Enhances the Antitumor Effects of the Oncolytic Virus M1.

Authors: Kai Li; Cheng Hu; Fan Xing; Mingshi Gao; Jiankai Liang; Xiao Xiao; Jing Cai; Yaqian Tan; Jun Hu; Wenbo Zhu; Wei Yin; Yuan Li; Wenli Chen; Bingzheng Lu; Jialuo Mai; Pengxin Qiu; Xingwen Su; Guangmei Yan; Haipeng Zhang; Yuan Lin
Journal: J Virol Date: 2018-02-26 Impact factor: 5.103

Review 3. Viroimmunotherapy for breast cancer: promises, problems and future directions.

Authors: Shyambabu Chaurasiya; Yuman Fong
Journal: Cancer Gene Ther Date: 2020-12-02 Impact factor: 5.987

Review 4. Oncolytic viruses and immunity.

Authors: Shyambabu Chaurasiya; Nanhai G Chen; Yuman Fong
Journal: Curr Opin Immunol Date: 2018-03-16 Impact factor: 7.268

Review 5. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses.

Authors: Kevin A Cassady; Kellie B Haworth; Josh Jackson; James M Markert; Timothy P Cripe
Journal: Viruses Date: 2016-02-04 Impact factor: 5.048

6. A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.

Authors: Julius W Kim; Jason Miska; Jacob S Young; Aida Rashidi; J Robert Kane; Wojciech K Panek; Deepak Kanojia; Yu Han; Irina V Balyasnikova; Maciej S Lesniak
Journal: Mol Ther Oncolytics Date: 2017-05-06 Impact factor: 7.200